At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 466 enrolled
Drug / intervention
Bimatoprost 0.01% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Bimatoprost 0.01% and Bimatoprost 0.03% for Glaucoma and Ocular Hypertension. Completed, enrolled 466 participants across 2 sites.
Detailed Summary
This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartJul 2013
Primary CompletionMay 2014
TodayJul 2026
First PostedApr 12, 2013
Enrollment StartJul 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.2 years ago
Interventions
Bimatoprost 0.01%drug
Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
Bimatoprost 0.03%drug
Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.